Evaluation Pembrolizumab (Keytruda): CADTH Reimbursement Suggestion: Sign: Together with chemotherapy, for the therapy of adult clients with locally recurrent unresectable or metastatic triple-negative breast cancer which have not obtained prior chemotherapy for metastatic illness and whose tumours Convey programmed mobile Dying-ligand one (combined constructive rating ≥ ten) as based on https://heinzv432nrp4.mycoolwiki.com/user